Why Henry Schein (HSIC) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
HSIC - Henry Schein, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$92.33
DETAILS
HIGH:
$110.00
LOW:
$64.00
MEDIAN:
$95.00
CONSENSUS:
$92.33
UPSIDE:
2.15%
Stock News
Is Henry Schein (HSIC) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
505,999 Shares in Henry Schein, Inc. $HSIC Purchased by Bank of New York Mellon Corp
Bank of New York Mellon Corp purchased a new stake in Henry Schein, Inc. (NASDAQ: HSIC) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 505,999 shares of the company's stock, valued at approximately $42,261,000. Bank of New York
HSIC vs. SAUHY: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Henry Schein (HSIC) and Straumann Holding AG (SAUHY). But which of these two stocks is more attractive to value investors?
Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is HSIC Worth Buying as Growth Improves but Execution Risks Persist?
Henry Schein's broader growth, recurring technology revenues and savings plan support its outlook, but leverage and execution risks remain key concerns.
HSIC Raises 2026 Outlook as Sales and Margin Momentum Accelerates
Henry Schein's stronger Q2 sales and margins prompt a 2026 outlook hike, but second-half savings execution remains key to sustaining earnings momentum.
Empowered Funds LLC Has $851,000 Position in Henry Schein, Inc. $HSIC
Empowered Funds LLC lessened its stake in Henry Schein, Inc. (NASDAQ: HSIC) by 59.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 11,551 shares of the company's stock after selling 16,735 shares during the period. Empowered Funds LLC's holdings in Henry Schein
Henry Schein (HSIC) is a Top-Ranked Growth Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Henry Schein (HSIC) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should Value Investors Buy Henry Schein (HSIC) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
HSIC or SAUHY: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Dental Supplies stocks have likely encountered both Henry Schein (HSIC) and Straumann Holding AG (SAUHY). But which of these two stocks presents investors with the better value opportunity right now?
Henry Schein, Inc. (HSIC) Hits Fresh High: Is There Still Room to Run?
Henry Schein (HSIC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Henry Schein, Inc. (HSIC) Q2 2026 Earnings Call Transcript
Henry Schein, Inc. (HSIC) Q2 2026 Earnings Call Transcript
Henry Schein Q2 Earnings Call Highlights
Henry Schein NASDAQ: HSIC reported higher second-quarter sales, operating margins and earnings, citing accelerating internal sales growth, market-share gains in dental merchandise and early benefits from its value-creation program. The company also raised its full-year sales and adjusted earnings guidance.
HSIC Surpasses Q2 Earnings and Revenue Estimates, Stock Climbs
Henry Schein tops Q2 earnings and revenue estimates as internal sales growth accelerates and management raises its 2026 outlook, lifting shares.
Henry Schein (HSIC) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Henry Schein (HSIC) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Henry Schein (HSIC) Q2 Earnings and Revenues Beat Estimates
Henry Schein (HSIC) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $1.1 per share a year ago.
Did Henry Schein Inc (HSIC) Just Beat EPS Estimates with Q2 Earnings? GF Score: 81/100, 2.7% Overvalued
Henry Schein Inc (HSIC) released its 8-K filing on August 4, 2026, reporting impressive financial results for the second quarter wrapped up on June 27, 2026. Th
Henry Schein Reports Strong Second Quarter 2026 Financial Results and Raises FY2026 Guidance
MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, today reported financial results for the second quarter ended June 27, 2026. “We delivered strong sales performance and margin improvement in the second quarter, driven by sustained momentum across our businesses and solid operational execution by the team. Internal local currency sales growth accelerated compared to the first.
Price Targets
Henry Schein price target raised to $110 from $100 at BTIG
$110.00
(was $90.61)
David Larsen
·
BTIG
Henry Schein price target raised to $100 from $86 at Barclays
$100.00
(was $89.59)
Barclays
Henry Schein price target raised to $104 from $97 at Barrington
$104.00
(was $89.11)
Michael Petusky
·
Barrington
Henry Schein price target raised to $94 from $89 at UBS
$94.00
(was $89.11)
Kevin Caliendo
·
UBS
Henry Schein price target raised to $95 from $84 at Stifel
$95.00
(was $89.11)
Stifel Nicolaus
Henry Schein price target raised to $89 from $85 at UBS
$89.00
(was $85.88)
UBS
Henry Schein initiated with a Market Perform at BMO Capital
$85.00
(was $83.22)
Vik Chopra
·
BMO Capital
BTIG upgrades Henry Schein to Buy on 'healthy' dental markets
$100.00
(was $78.85)
BTIG
Henry Schein price target lowered to $85 from $87 at UBS
$85.00
(was $74.35)
Kevin Caliendo
·
UBS
Henry Schein price target lowered to $82 from $88 at Mizuho
$82.00
(was $74.37)
Mizuho Securities
Henry Schein price target lowered to $97 from $104 at Baird
$97.00
(was $74.37)
Robert W. Baird
Henry Schein price target raised to $64 from $61 at Morgan Stanley
$64.00
(was $78.22)
Erin Wright
·
Morgan Stanley
Henry Schein price target raised to $97 from $79 at Barrington
$97.00
(was $81.60)
Barrington
Henry Schein price target raised to $87 from $75 at Leerink
$87.00
(was $83.35)
Leerink Partners
Henry Schein upgraded to Outperform from Neutral at Baird
$100.00
(was $79.57)
Robert W. Baird
Henry Schein price target raised to $81 from $74 at Mizuho
$81.00
(was $79.98)
Steven Valiquette
·
Mizuho Securities
Henry Schein initiated with an Overweight at Barclays
$86.00
(was $72.86)
Barclays
Henry Schein price target raised to $90 from $83 at Evercore ISI
$90.00
(was $71.69)
Evercore ISI
Henry Schein price target raised to $79 from $78 at Barrington
$79.00
(was $71.32)
Barrington
Henry Schein upgraded to Outperform from In Line at Evercore ISI
$83.00
(was $69.04)
Evercore ISI